{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:00:43Z","timestamp":1786122043685,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100015501","name":"Qu\u1ef9 \u0110\u1ed5i m\u1edbi s\u00e1ng t\u1ea1o Vingroup","doi-asserted-by":"publisher","award":["VINIF.2021.TS"],"award-info":[{"award-number":["VINIF.2021.TS"]}],"id":[{"id":"10.13039\/501100015501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015501","name":"Qu\u1ef9 \u0110\u1ed5i m\u1edbi s\u00e1ng t\u1ea1o Vingroup","doi-asserted-by":"publisher","award":["VINIF.2019.15"],"award-info":[{"award-number":["VINIF.2019.15"]}],"id":[{"id":"10.13039\/501100015501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16271-0","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:15:18Z","timestamp":1780496118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood circulating C228T TERT gene promoter mutation is an independent factor for the prognosis of HBV\u2013related hepatocellular carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Pham","family":"Quang Trung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong","family":"Quang Huy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghiem","family":"Xuan Hoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Reboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen","family":"Linh Toan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Huu Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngo","family":"Tat Trung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"3","key":"16271_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"16271_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","volume":"70","author":"N Ganne-Carri\u00e9","year":"2019","unstructured":"Ganne-Carri\u00e9 N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70(2):284\u201393.","journal-title":"J Hepatol"},{"issue":"1","key":"16271_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/hep.31558","volume":"73","author":"N Mahmud","year":"2021","unstructured":"Mahmud N, et al. Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis. Hepatology. 2021;73(1):204\u201318.","journal-title":"Hepatology"},{"issue":"15","key":"16271_CR4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"9","key":"16271_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrc1934","volume":"6","author":"PA Farazi","year":"2006","unstructured":"Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674\u201387.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"16271_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118\u201327.","journal-title":"N Engl J Med"},{"issue":"9822","key":"16271_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245\u201355.","journal-title":"Lancet"},{"issue":"6","key":"16271_CR8","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/hep.27372","volume":"60","author":"JC Nault","year":"2014","unstructured":"Nault JC, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014;60(6):1983\u201392.","journal-title":"Hepatology"},{"issue":"12","key":"16271_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ng.3126","volume":"46","author":"Y Totoki","year":"2014","unstructured":"Totoki Y, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46(12):1267\u201373.","journal-title":"Nat Genet"},{"issue":"7","key":"16271_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Electronic address, w.b.e. and N. Cancer Genome Atlas Research, Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017;169(7):1327\u2013e134123.","journal-title":"Cell"},{"issue":"9","key":"16271_CR11","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1101\/gr.154492.113","volume":"23","author":"Z Kan","year":"2013","unstructured":"Kan Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23(9):1422\u201333.","journal-title":"Genome Res"},{"key":"16271_CR12","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/ncomms3218","volume":"4","author":"JC Nault","year":"2013","unstructured":"Nault JC, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218.","journal-title":"Nat Commun"},{"issue":"6265","key":"16271_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1126\/science.aab3389","volume":"350","author":"EH Blackburn","year":"2015","unstructured":"Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350(6265):1193\u20138.","journal-title":"Science"},{"issue":"7859","key":"16271_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-021-03529-9","volume":"593","author":"Y He","year":"2021","unstructured":"He Y, et al. Structures of telomerase at several steps of telomere repeat synthesis. Nature. 2021;593(7859):454\u20139.","journal-title":"Nature"},{"issue":"6122","key":"16271_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn S, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959\u201361.","journal-title":"Science"},{"issue":"6122","key":"16271_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang FW, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957\u20139.","journal-title":"Science"},{"issue":"1","key":"16271_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clinre.2015.07.006","volume":"40","author":"JC Nault","year":"2016","unstructured":"Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40(1):9\u201314.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"16271_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13027-017-0138-5","volume":"12","author":"F Pezzuto","year":"2017","unstructured":"Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer. 2017;12:27.","journal-title":"Infect Agent Cancer"},{"issue":"9","key":"16271_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41575-019-0165-3","volume":"16","author":"JC Nault","year":"2019","unstructured":"Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019;16(9):544\u201358.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"16271_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00401-013-1198-2","volume":"126","author":"M Remke","year":"2013","unstructured":"Remke M, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013;126(6):917\u201329.","journal-title":"Acta Neuropathol"},{"key":"16271_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.wneu.2019.07.111","volume":"130","author":"A Deniel","year":"2019","unstructured":"Deniel A, et al. TERTp Mutation Detection in Plasma by Droplet-Digital Polymerase Chain Reaction in Spinal Myxopapillary Ependymoma with Lung Metastases. World Neurosurg. 2019;130:405\u20139.","journal-title":"World Neurosurg"},{"issue":"4","key":"16271_CR22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/ijc.32216","volume":"145","author":"D Braig","year":"2019","unstructured":"Braig D, et al. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas. Int J Cancer. 2019;145(4):1148\u201361.","journal-title":"Int J Cancer"},{"issue":"2","key":"16271_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/1878-0261.12391","volume":"13","author":"L Calapre","year":"2019","unstructured":"Calapre L, et al. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol. 2019;13(2):171\u201384.","journal-title":"Mol Oncol"},{"issue":"2","key":"16271_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000514312","volume":"4","author":"M Kudo","year":"2015","unstructured":"Kudo M. Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer. 2015;4(2):85\u201395.","journal-title":"Liver Cancer"},{"key":"16271_CR25","unstructured":"Kokudo N et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res, 2015. 45(2)."},{"issue":"2","key":"16271_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"4","key":"16271_CR27","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"key":"16271_CR28","unstructured":"Amin MB et al. AJCC cancer staging manual. 8th ed. New York:. Springer; 2017. [Google Scholar], 2017."},{"issue":"6","key":"16271_CR29","first-page":"85","volume":"110","author":"J Wiegand","year":"2013","unstructured":"Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int. 2013;110(6):85\u201391.","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"16271_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"1","key":"16271_CR31","doi-asserted-by":"publisher","first-page":"8181","DOI":"10.1038\/s41598-020-65213-8","volume":"10","author":"NT Trung","year":"2020","unstructured":"Trung NT, et al. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma. Sci Rep. 2020;10(1):8181.","journal-title":"Sci Rep"},{"key":"16271_CR32","doi-asserted-by":"publisher","first-page":"78890","DOI":"10.18632\/oncotarget.20354","volume":"8","author":"AC McEvoy","year":"2017","unstructured":"McEvoy AC, Pereira CL, Giardina MR, Robinson T, Khattak C, Meniawy MA, Pritchard TM, Hayward AL, Amanuel NK, Millward B, Ziman M, Gray M. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget. 2017;8:78890\u2013900.","journal-title":"Oncotarget"},{"issue":"4","key":"16271_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","volume":"1","author":"MK Goel","year":"2010","unstructured":"Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1(4):274\u20138.","journal-title":"Int J Ayurveda Res"},{"issue":"2","key":"16271_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/hep.20308","volume":"40","author":"A Satyanarayana","year":"2004","unstructured":"Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology. 2004;40(2):276\u201383.","journal-title":"Hepatology"},{"issue":"35","key":"16271_CR35","doi-asserted-by":"publisher","first-page":"e11794","DOI":"10.1097\/MD.0000000000011794","volume":"97","author":"K Wang","year":"2018","unstructured":"Wang K, et al. The prognostic significance of hTERT overexpression in cancers: A systematic review and meta-analysis. Med (Baltim). 2018;97(35):e11794.","journal-title":"Med (Baltim)"},{"key":"16271_CR36","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/bjc.2014.538","volume":"111","author":"M Labussiere","year":"2014","unstructured":"Labussiere M, Gleize ALDSV, Boisselier B, Giry M. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer. 2014;111:2024\u201332.","journal-title":"Br J Cancer"},{"issue":"4","key":"16271_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-13-0210","volume":"20","author":"X Liu","year":"2013","unstructured":"Liu X, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603\u201310.","journal-title":"Endocr Relat Cancer"},{"key":"16271_CR38","doi-asserted-by":"crossref","unstructured":"Landa I, Chan GI, Mitsutake TA, Matsuse N, Ibrahimpasic M, Ghossein T, Fagin RA. JA, Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013, 2013. 98.","DOI":"10.1210\/jc.2013-2383"},{"issue":"15","key":"16271_CR39","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela PJ, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"16271_CR40","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/jgh.15227","volume":"36","author":"M Hirai","year":"2021","unstructured":"Hirai M, et al. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. J Gastroenterol Hepatol. 2021;36(4):1118\u201325.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"16271_CR41","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1002\/jmv.25724","volume":"92","author":"N Akuta","year":"2020","unstructured":"Akuta N, et al. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma. J Med Virol. 2020;92(12):3604\u20138.","journal-title":"J Med Virol"},{"issue":"5","key":"16271_CR42","doi-asserted-by":"publisher","first-page":"e5766","DOI":"10.1097\/MD.0000000000005766","volume":"96","author":"HW Lee","year":"2017","unstructured":"Lee HW, et al. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma. Med (Baltim). 2017;96(5):e5766.","journal-title":"Med (Baltim)"},{"key":"16271_CR43","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2147\/JHC.S385026","volume":"9","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhang X, Yu J. Integrated Analysis of Altered lncRNA, circRNA, microRNA, and mRNA Expression in Hepatocellular Carcinoma Carrying TERT Promoter Mutations. J Hepatocell Carcinoma. 2022;9:1201\u201315.","journal-title":"J Hepatocell Carcinoma"},{"issue":"19","key":"16271_CR44","doi-asserted-by":"publisher","first-page":"27838","DOI":"10.18632\/oncotarget.8539","volume":"7","author":"X Yang","year":"2016","unstructured":"Yang X, et al. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget. 2016;7(19):27838\u201347.","journal-title":"Oncotarget"},{"key":"16271_CR45","doi-asserted-by":"crossref","unstructured":"Jang JW et al. Significance TERT Genetic Alterations Telomere Length Hepatocellular Carcinoma 2021. 13(9).","DOI":"10.3390\/cancers13092160"},{"key":"16271_CR46","doi-asserted-by":"crossref","unstructured":"Oversoe SK, Clement MS, Pedersen MH, Weber B. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. 2020. 55(12): pp. 1433\u201340.","DOI":"10.1080\/00365521.2020.1837928"},{"issue":"16","key":"16271_CR47","doi-asserted-by":"publisher","first-page":"26288","DOI":"10.18632\/oncotarget.15458","volume":"8","author":"W Huang","year":"2017","unstructured":"Huang W, et al. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma. Oncotarget. 2017;8(16):26288\u201397.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16271-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:53:55Z","timestamp":1786089235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16271"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16271-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures were approved by the 108 Military Central Hospital, Hanoi, Vietnam (project VINIF.2019.15). The requirement for written patient informed consent was waived by 108 Military Central Hospital Institutional Review Board due to the study design.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent of publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"942"}}